Validation of densitometric and videodensitometric TLC methods for analysis of vigabatrin in pharmaceutical formulations
PDF

Keywords

TLC
densitometry
videodensitometry
vigabatrin
tablets

Abstract

Two new, simple, precise and accurate thin-layer chromatography methods with densitometric and videodensitometric detection were developed for the determination of vigabatrin in pharmaceutical preparations. The analysis was performed on silica gel 60 F254 plates in horizontal chambers with acetone-butan-2-one-formic acid-water (40:45:5:10, v/v), as mobile phase. The method is based on the reaction of the primary amino group of vigabatrin with ninhydrin reagent producing a colored product which absorbs maximally at 483 nm. Videodensitometric assay was performed at visible light. Calibration plots were constructed in the range 2.0 - 20.0 µg/spot with good correlation coefficients r=0.9991 and r=0.9949 for densitometry and videodensitometry, respectively. The LOD was 0.6 µg and 0.8 µg per spot for densitometric and videodensitometric assay, respectively; the LOQ was 1.5 µg per spot for both methods. The active substance was extracted from tablets with methanol. The mean ± SD recovery from commercially available tablets was 100.22 ± 0.61% (n=6) for the both methods. Tablet excipients did not interfere with the chromatography. Finally, the methods were compared statistically in respect of precision and accuracy. No significant differences were observed.

PDF

References

1. Al-Majed A.: A direct HPLC method for the resolution and quantitation of the R-(-)-and S-(+)-enantiomers of vigabatrin (γ-vinyl-GABA) in pharmaceutical dosage forms using teicoplanin aglycone chiral stationary phase. J. Pharm. Biomed. Anal., 50, 96, 2009.

2. Al-Zehouri J., Al-madi S., Belal F.: Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction. Arzneim.- Forsch. Drug Res. 51, 97, 2001.

3. Belal F. et al.: Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine. J. Pharm. Biomed. Anal., 27, 253, 2002.

4. Cetin S.M. and Atmaca S.: Determination of vigabatrin in tablets by high performance liquid chromatography. Acta Pharmaceutica Turcica, 44, 57, 2002.

5. Chen T.M., Contario J.J., Fike R.R.: High-performance liquid chromatographic assay for vigabatrin and its primary degradation product in a pharmaceutical tablet formulation. J. Chromatogr. 398, 351, 1987.

6. Ekram M.H. et al.: Spectrofluorimetric determination of vigabatrin and gabapentin in dosage forms and spiked plasma samples through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole. J.AOAC Int., 84, 993, 2001.

7. Johannessen B.D. et al.: Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit., 25, 347, 2003.

8. Johannessen S.I. and Tomson T.: Pharmacokinetic Variability of Newer Antiepileptic Drugs. Clin. Pharmacokinet., 45, 1061, 2006.

9. Lin F.M. et al.: Capillary electrophoresis analysis of gabapentin and vigabatrin in pharmaceutical preparations as ofloxacin derivatives. Analytica Chimica Acta, 523, 9, 2004.

10. Olgun N., Erturuk S., Atmaca S.: Spectrofluorimetric and spectrophotometric methods for the determination of vigabatrin in tablets. J. Pharm. Biomed. Anal., 29, 1, 2002.

11. Shafaati A. and Lucy C.: Application of capillary zone electrophoresis with indirect UV detection to the determination of a model drug, vigabatrin, in dosage forms. J. Pharm. Pharmaceut. Sci, 8, 190, 2005.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

Copyright (c) 2012 Author

Downloads

Download data is not yet available.